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Nitric oxide (NO) is a ubiquitous signaling molecule involved in a wide variety of cellular physio-
logical processes. In thyroid cells, NO-synthase III-endogenously produced NO reduces TSH-stim-
ulated thyroid-specific gene expression, suggesting apotential autocrine role ofNO inmodulating
thyroid function. Further studies indicate that NO induces thyroid dedifferentiation, because NO
donors repress TSH-stimulated iodide (I) uptake. Here,we investigated themolecularmechanism
underlying the NO-inhibited Na/I symporter (NIS)-mediated I uptake in thyroid cells. We
showed that NO donors reduce I uptake in a concentration-dependentmanner, which correlates
with decreased NIS protein expression. NO-reduced I uptake results from transcriptional repres-
sion of NIS gene rather than posttranslational modifications reducing functional NIS expression at
the plasma membrane. We observed that NO donors repress TSH-induced NIS gene expression by
reducing the transcriptional activity of the nuclear factor-B subunit p65. NO-promoted p65 S-
nitrosylation reduces p65-mediated transactivation of the NIS promoter in response to TSH stim-
ulation. Overall, our data are consistentwith the notion that NOplays a role as an inhibitory signal
to counterbalance TSH-stimulated nuclear factor-B activation, thusmodulating thyroid hormone
biosynthesis. (Endocrinology 156: 4741–4754, 2015)
Iodide (I
) plays a key role in thyroid physiology as an
essential component of the thyroid hormones and as a
regulator of thyroid function (1, 2). Na/I symporter
(NIS)-mediated I uptake across the basolateral plasma
membrane of thyrocytes constitutes the first step in thy-
roid hormone biosynthesis (2). TSH is the main regulator
of I uptake and NIS expression in thyroid cells. TSH-
induced cAMP production stimulates I transport by in-
creasing NIS gene transcription (3, 4). The regulatory re-
gion controlling rat NIS gene expression contains a
proximal promoter between nucleotides110 and420
relative to the transcription start site, and a strong TSH-
responsive far-upstream enhancer (NIS upstream en-
hancer [NUE]) between nucleotides 2264 and 2495
(4). The NUE region contains 2 thyroid transcription fac-
tor 1-binding sites that have no apparent effect on NIS
transcription, 2 paired box 8 (Pax8)-binding sites, and a
degenerate cAMP-response element. Full TSH-dependent
NISgene transcription requires at least 1Pax8-binding site
and the integrity of the cAMP-response element sequence
(5). We have previously described the role of the nuclear
factor (NF)-B subunit p65 in the regulation of NIS gene
transcription through direct interaction with an NF-B-
binding site within the NUE region (6). In addition, the
transcription factor p65 functionally cooperates with
Pax8 in the regulation of NIS gene expression (6).
Nitric oxide (NO) is a ubiquitous signaling molecule
involved in a wide variety of physiological processes.
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However, chronic overproduction of NO is associated
with various cancerous and autoimmune diseases (7, 8).
EndogenousNO is generated fromL-arginine byNO syn-
thase (NOS). The members of the NOS family, named
NOS I–III, are widely expressed. In particular, NOS III is
abundantly expressed in the thyroid follicular cells (9, 10),
and basal levels of endogenous NO-induced cyclic
guanosinemonophosphate (cGMP) production have been
reported (11).Gérard et al (12) demonstrated thatNOS III
expression is restricted to active thyroid follicles, suggest-
ing a paracrine role for NO in the modulation of micro-
vascular blood flow. Moreover, NO donors have been
reported to inhibit I uptake and organification in various
thyroid cell models (13–15). We have previously investi-
gated the role of endogenous NO production in thyroid
cell function and differentiation using nonselective NOS
inhibitors, and concluded that endogenous NO acts as a
negative regulator of TSH-stimulated gene expression and
proliferation in thyrocytes (16). Together, these results
suggest that NO participates in an inhibitory autocrine
feedback loop in the regulation ofTSH-dependent thyroid
cell function.
The best characterized physiological mediator of NO
action, known as the canonical signaling pathway, is the
soluble guanylate cyclase. NO activates soluble guanylate
cyclase to produce the secondary messenger cGMP, thus
activating cGMP-dependent protein kinases (cGKs) (17).
In addition, a noncanonical, cGMP-independent NO sig-
naling pathway involves the posttranslational S-nitrosy-
lation of specific cysteine residues to regulate protein
structure and activity (17). Compelling evidence suggests
thatNOregulates gene expressionbymodulating the tran-
scriptional activity of many transcription factors through
S-nitrosylation (18). Indeed, S-nitrosylation is the primary
molecularmechanismbywhichNOmodulatesNF-Bsig-
naling (19). S-nitrosylation regulates the inhibitor of
NF-B kinase  (IKK-) and the transcriptionally active
NF-B subunits p50 and p65. In particular, S-nitrosyla-
tion of p65 at cysteine 38 (Cys-38) inhibits p65 DNA
binding and p65-dependent gene transcription (20).
Various studies have demonstrated that the classical
NO donor sodium nitroprusside (SNP) down-regulates
TSH-induced I uptake in thyroid cells (13–15). Accord-
ingly, inhibition of NOS activity, resulting in suppression
of NO production, increases TSH-stimulated I uptake
(16). Therefore, investigationof themolecularmechanism
by which NO regulates I uptake could provide critical
information regarding the role ofNO inmodulatingTSH-
induced thyroid hormonogenesis. Thus, we have exam-
ined the mechanism involved in the NO-induced inhibi-
tion of NIS-mediated I uptake in thyroid cells. Here, we
provide evidence supporting the notion that NO-modu-
lated NIS gene transcriptional expression involves S-ni-
trosylation of the NF-B subunit p65, which reduces
transactivation of the NIS promoter in response to TSH
stimulation.
Materials and Methods
Plasmids
The 2854 to 13-bp DNA fragment (pNIS-2.8) of the rat
NIS promoter and the NIS enhancer region (NUE)-deleted
construct (pNIS-2.0) were as described (21). The 2495 to
2264-bp DNA fragment of the far-upstream enhancer NUE
cloned 5 upstream to the thymidine kinase promoter (pNUE)
and its site-directed mutants were as reported (5, 6). The NF-B
reporter vector containing 5 B consensus sites linked to the
luciferase coding sequence (pNF-B-Luc) was obtained from
Clontech. The Pax8 reporter gene (5xPax8-Luc) and the cAMP-
responsive gene (5xCRE-Luc) were as described (22, 23). The
normalization reporter pCMV--galactosidase was purchased
from Promega. Expression vectors encoding amino-terminal
hemagglutinin (HA)-tagged wild-type NIS (HA-NIS), flag-
tagged wild-type p65, and flag-tagged C38S p65 were as re-
ported (24–26).
Cell culture
The thyroid cell line Fisher rat thyroid cell line 5 (FRTL-5)
(ATCC CRL-1468) was cultured in DMEM/Ham F-12 me-
dium supplemented with 5% calf serum (Life Technologies),
1-mIU/mL bovine TSH (National Hormone and Peptide Pro-
gram), 10-g/mL bovine insulin, and 5-g/mL bovine transfer-
rin (Sigma-Aldrich) (27). FRTL-5 cells stably expressingHA-NIS
were selected and propagated in growth media containing 300-
g/mL G418 (Sigma-Aldrich). When cells reached 50%–60%
confluence, theywere cultured in the samemedia exceptwithout
TSH and containing only 0.2% calf serum (basal media) for 5
days before treatment. TSH-starved cells were treated with differ-
ent concentrations of SNP (Calbiochem), S-nitrosoglutathione
(GSNO) (Sigma-Aldrich), or spermineNONOate (SPNO) (Sigma-
Aldrich) in the absence or presence of 0.5-mIU/mL TSH for the
indicated periods of time. The NO scavenger 2-(4-carboxyphe-
nyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO)
(Sigma-Aldrich) was used in an amount equimolar to the con-
centration of NO donors. After treatments, cell viability was
higher than 95%, as determined by the Trypan blue dye exclu-
sion assay (see Supplemental Materials and Methods).
I uptake
Cells were incubated in modified Hanks’ balanced salt solu-
tion (10mM HEPES [pH 7.5], 140mM NaCl, 5.4mM KCl,
1.3mM CaCl2, 0.4mM MgSO4, 0.5mM MgCl2, 0.4mM
Na2HPO4, 0.44mM KH2PO4, and 5.6mM glucose) containing
20M NaI supplemented with 10 Ci/mol I carrier-free
Na125I (PerkinElmer Life and Analytical Sciences) for 30 min-
utes at 37°C (28). Accumulated radioiodide was extracted with
95% ice-cold ethanol and then quantified in a -counter (Beck-
man Gamma 4000, Beckman Coulter). The DNA amount was
determined by the diphenylamine method on the nonethanol
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extractedmaterial after trichloroacetic acid precipitation. I up-
take was expressed as pmol I/g DNA.
Cell surface biotinylation
FRTL-5 cells were incubated with 0.5-mg/mL sulfo-NH-SS-
biotin (Pierce Biotechnology) in 20mM HEPES (pH 8.5), 2mM
CaCl2, and 150mMNaCl for 15minutes at 4°C. Excess of sulfo-
NH-SS-biotin was quenched with PBS containing 100mM gly-
cine. Cells were lysed in 50mM Tris-HCl (pH 7.5), 150mM
NaCl, 5mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl
sulfate (SDS) at 4°C for 20 minutes. 100 g protein was incu-
bated overnight at 4°C with streptavidin agarose beads (Pierce
Biotechnology). Beads were washed and adsorbed proteins were
eluted with sample buffer at 75°C for 5minutes and analyzed by
immunoblotting as described below.
Flow cytometry
Paraformaldehyde-fixed cells were incubated in PBS contain-
ing 0.2%BSA for nonpermeabilized conditions or an additional
0.2% saponin for permeabilized conditions with 1:800 rabbit
monoclonal anti-HA antibody (Cell Signaling), followed by 0.4-
g/mL Alexa Fluor 488-conjugated goat antirabbit antibody
(Molecular Probes). The fluorescence of 2  104 cells per ex-
perimental samplewas assayed in FACSCanto II flow cytometer
(BD Biosciences). All data were analyzed with FlowJo software
(Tree Star).
Immunoblotting
For total protein extracts, FRTL-5 cells were resuspended in
whole-cell lysate buffer (50mM HEPES [pH 7], 2mM MgCl2,
250mM NaCl, 0.1mM EDTA, 0.1mM EGTA, 0.1% Nonidet
P-40) supplemented with protease inhibitors, and incubated on
ice for 15 minutes (29). Cytoplasmic and nuclear protein frac-
tionation was performed using ProteoJET extraction kit (Fer-
mentas Life Sciences). Polypeptides were resolved by SDS-PAGE
and electrotransferred to nitrocellulose membranes (Whatman).
Information regarding primary antibodies is presented in Table
1. Proteins were visualized by the enhanced chemiluminescence
Western blotting detection system (Pierce Biotechnology). Band
intensities were measured densitometrically using ImageJ Soft-
ware (National Institutes of Health).
Real-time PCR
Total RNA purification, cDNA synthesis, and quantitative
PCR (qPCR) were performed as described (30). Gene-specific
primer sets were as follow: NIS (270 bp), 5-GCTGTGGCAT
TGTCATGTTC (forward) and 5-TGAGGTCTTCCACAGT
CACA (reverse); Pax8 (256 bp), 5- CAGTTGTCGACTGAG
CATCG (forward) and 5- GCGTCCCAGAGGTGTATTGG
(reverse); NF-B inhibitor (IB)- (217 bp), 5-CCGAGACTT
TCGAGGAAATACC (forward) and 5-GAGCGTTGACATC
AGCACC (reverse); and -actin (138 bp), 5-GGCACCAC
ACTTTCTACAATG (forward) and 5-TGGCTGGGGTG
TTGAAGGT(reverse).Relative changes in gene expressionwere
calculated using the 2Ct method normalized against the
housekeeping gene -actin. Primers used for chromatin immu-
noprecipitation (ChIP) analysis were as reported (6). For each
pair of primers a dissociation plot resulted in a single peak, in-
dicating that only 1 PCR product was amplified. Specific target
amplification was confirmed by automatic sequencing (Macro-
gen). qPCR efficiency for each pair of primers was calculated
using standard curves generated by serial dilutions of cDNA or
genomic DNA of FRTL-5 cells. All qPCR efficiencies ranged
between 97%–105% in different assays.
Transient transfection and reporter gene assay
FRTL-5 cells were transiently transfected with 2 g of lu-
ciferase reporter-promoter constructs per well in 6-well plates
using Lipofectamine 2000 (Life Technologies). To study pro-
moter activity, cells were split into 24-well plates at 80% con-
fluence the day after transfection. The next day, growth media
was replacedwith basalmedia and transfected cells were starved
and treated as stated above. The luciferase activitywasmeasured
using a Luciferase Assay System (Promega) according to manu-
Table 1. Antibody Table
Peptide/
Protein
Target Antigen Sequence
Name of
Antibody
Manufacturer, Catalog
Number, and/or Name
of Individual Providing
the Antibody
Species Raised in;
Monoclonal or
Polyclonal
Dilution
Used
NIS Proprietary — Dr Nancy Carrasco Rabbit; Polyclonal 0.4 g/mL
p65 C terminus of human p65 C-20 sc-372G, Santa Cruz
Biotechnology, Inc
Goat; polyclonal 2 g/mL
Pax8 C terminus of human Pax8 PAX8R1 sc-81353, Santa Cruz
Biotechnology, Inc
Mouse; monoclonal 2 g/mL
IB- Full-length human IB- H-4 sc-1643, Santa Cruz
Biotechnology, Inc
Mouse; monoclonal 4 g/mL
TSHR Amino acids 1–155 of human
TSHR
H-155 sc-13936, Santa Cruz
Biotechnology, Inc
Rabbit; polyclonal 1 g/mL
TPO TPO purified from human
thyroid microsomes
MoAb47 sc-58432, Santa Cruz
Biotechnology, Inc
Mouse; monoclonal 8 g/mL
Histone H1 Unknown AE-4 sc-8030, Santa Cruz
Biotechnology, Inc
Mouse; monoclonal 1 g/mL
HA-Tag YPYDVPDYA C29F4 3724, Cell Signaling Rabbit; monoclonal 1:1000
Flag-Tag DYKDDDDK — F7425, Sigma-Aldrich Rabbit; polyclonal 1 g/mL
-Actin DDDIAALVIDDGSGK AC-15 A1978, Sigma-Aldrich Mouse; monoclonal 0.5 g/mL
-Tubulin Unknown B-5-1-2 T5168, Sigma-Aldrich Mouse; monoclonal 0.2 g/mL
E-cadherin Amino acids 735–883 of
human E-cadherin
Clone 36/
E-cadherin
610181, BD Transduction
Laboratories
Mouse; monoclonal 0.25 g/mL
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facturer’s instructions. To assess transfection efficiency, cells
were cotransfected with 0.2 g/well of the normalization re-
porter-galactosidase. Luciferase activitieswere normalized rel-
ative to -galactosidase activity values.
When the effect of C38S p65 was tested, FRTL-5 cells were
cotransfected with luciferase reporter-promoter constructs (0.9
g), p65 expression vectors (2.6 g), and -galactosidase re-
porter vector (0.1 g) per well of a 6-well plate.
Biotin-switch assay for S-nitrosylation
The biotin switch assay was performed in virtual darkness as
previously described (31). In brief, FRTL-5 cells were disrupted
by gentle sonication in HEN buffer (100mM HEPES [pH 7.8],
1mM EDTA, and 0.1mM neocuproine). Typically, 600 g of
total proteins were incubated in blocking buffer (2.5% SDS and
20mM N-ethylmaleimide in HEN buffer) to block-free thiol
groups. After removing excess N-ethylmaleimide by acetone
precipitation, nitrosothiols were reduced to thiols with 3mM
ascorbic acid. The newly formed thiols were then linked to the
sulfhydryl-specific biotinylating reagent N-[6-(biotinamido)
hexyl]-3-(2-pyridyldithio) propionamide (Pierce Biotechnol-
ogy). After removing excess N-[6-(biotinamido)hexyl]-3-(2-
pyridyldithio) propionamide by acetone precipitation, biotinylated
proteinsweredilutedto1mg/mL in neutralization buffer (20mM
HEPES [pH 7.7], 100mMNaCl, 1mMEDTA, 0.1% SDS, and
0.5% Triton X-100) and pulled down using neutralization
buffer-equilibrated streptavidin-agarose beads (Sigma-Al-
drich). The resin was washed 5 times with neutralization buf-
fer containing 600mMNaCl, twice with neutralization buffer
containing 1M NaCl and once with regular neutralization
buffer. Bound-proteins were eluted in Laemmli sample buffer
containing 1% 2-mercaptoethanol and Western blot analysis
to detect the S-nitrosylated proteins was performed as de-
scribed above.
Chromatin immunoprecipitation
ChIP assays were performed as previously described (29).
Briefly, cells were cross-linked in culture media containing 1%
formaldehyde. Nuclei were purified and lysed in 50mM Tris-
HCl (pH 8), 10mM EDTA, and 1% SDS. Genomic DNA was
broken by sonication and 10-fold diluted in IP dilution buffer
(50mM Tris-HCl [pH 7.5], 150mM NaCl, 5mM EDTA, 1%
Triton X-100, and 0.5% Nonidet P-40). Immunoprecipitation
was performed with 2 g of affinity-purified monoclonal anti-
p65 antibody (sc-8008; Santa Cruz Biotechnology, Inc) or con-
trol mouse IgG. Immune complexes were purified with Protein
A/G PLUS-Agarose (Santa Cruz Biotechnology, Inc). Immuno-
precipitates were washed 4 times with IP dilution buffer con-
taining 0.1% SDS; twice with high-salt IP wash buffer (50mM
Tris-HCl [pH 7.5], 500mMNaCl, 5mMEDTA, 0.1% SDS, and
1% Triton X-100), and once with 10-mM Tris-HCl (pH 8) and
1-mM EDTA. DNA was purified using Chelex-100 (Bio-Rad).
Immunoprecipitated DNA was quantified by qPCR as mentioned
above. Relative fold increasewas calculated according to the equa-
tion: 2 [Ct.input  Ct.target)  (Ct.input  Ct.mock)].
Statistical analysis
Results are reported as the mean  SD. One-way ANOVA
with Newman-Keuls multiple comparisons post hoc test was
performed using GraphPad Prism (GraphPad Software) from at
least 3 independent experiments. Differences were considered
statistically significant at P  .05.
Results
NO donors inhibit TSH-induced I uptake
Previous studies have shown that NO donors inhibit
TSH-stimulated I uptake in various thyroid cell models
(13–15). Therefore, to understand the molecular mecha-
nism involved in NO-inhibited I uptake, we first deter-
mined the effect of different NO donors on TSH-induced
I uptake in FRTL-5 thyroid cells. Thyroid cells were
treated with different concentrations of one of 3 structur-
ally unrelated NO donors, SNP, GSNO, or SPNO, in the
presence ofTSH (0.5mIU/mL) for 24hours.As previously
reported (13, 14), treatment of thyroid cells with SNP
(50M–500M) inhibited TSH-stimulated I uptake in a
concentration-dependent manner (Figure 1A). A similar
inhibitory effect was observed with the physiologically
relevant nitrosothiol GSNO (200M) and theNO-releas-
ing agent SPNO (100M), which yields approximately
physiological steady-state concentrations of NO (Figure
1B). Perchlorate (ClO4
), a competitive NIS inhibitor, re-
duced I accumulation to levels comparable with those of
TSH-starved cells, suggesting NIS-mediated I accumu-
lation (Supplemental Figure 1A). In addition, no NO do-
nors tested had a significant effect on I uptake in TSH-
starved cells (Supplemental Figure 1B). Nor was any
significant effect of NO donors observed on TSH-stimu-
lated I uptake in the presence of the cell-permeating NO
scavenger cPTIO (Figure 1B). Moreover, TSH-induced I
uptake was slightly higher when endogenously generated
NO was sequestered by cPTIO (Figure 1B) (16).
To analyze the mechanism underlying NO donor-in-
hibited I uptake, FRTL-5 cells were treated with TSH in
the presence or absence of NO donors, and NIS protein
expression at the plasma membrane was assessed using
cell surface biotinylation assays. As previously reported
(32), TSH stimulation increased NIS expression at the
plasma membrane (Figure 1C). However, NO donors re-
duced TSH-induced cell surface NIS levels (Figure 1C).
Considering that functional NIS expression at the plasma
membrane accounts for I accumulation, these results
provide a potential explanation for the reduction of NIS-
mediated I uptake in the presence of NO donors: NO
donors either impair the trafficking of NIS to the plasma
membraneor, alternatively, reduce thebiosynthesis ofNIS
protein.
NO donors do not modulate NIS expression at the
posttranscriptional level
To determinewhetherNOdonors repress the targeting
of NIS to the plasma membrane, we engineered FRTL-5
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cells stably expressing wild-type NIS containing a HA
epitope at the extracellular amino terminus (HA-NIS),
whose expression is controlled by a constitutive non-TSH-
regulated promoter. This system allows us to determine
the amount of NIS at the cell surface using an anti-HA
antibody under nonpermeabilized conditions. To deter-
mine the functionality and intracellular distribution of the
fusion protein, Cos-7 cells were transiently transfected
with vectors encoding wild-type NIS or HA-NIS. I up-
take assays showed that HA tagging does not affect NIS
function (Supplemental Figure 2A), suggesting that the
HA epitope does not affect targeting of NIS to the plasma
membrane. This was further confirmed by confocal mi-
croscopy (Supplemental Figure 2B). To determine theNO
donor-induced posttranslational mechanisms affecting
NIS function or cell surface expression, HA-NIS-express-
ing FRTL-5 cells were cultured without TSH to down-
regulate their endogenous NIS expression and further in-
cubated with NO donors for 24 hours. I uptake assays
demonstrated that NO donors do not significantly affect
the activity of the exogenous NIS fusion protein (Figure
2A). Immunoblot analysis using an anti-HA antibody
demonstrated constitutive expressionof the fusionprotein
despite the presence of TSH (Figure 2B). TPO expression
was measured to assess TSH responsiveness (Figure 2B).
Flow cytometry under nonpermeabilized conditions using
an anti-HA antibody demonstrated that NO donors did
not modify cell surface HA-NIS expression in FRTL-5
cells (Figure 2C, surface). Moreover, flow cytometry as-
sessing HA-NIS expression under permeabilized condi-
tions indicated that NO donors did not modulate total
HA-NIS expression (Figure 2C, total). Taken together,
these findings indicate that the decrease in I uptake
caused by NO donors is not due to internalization of NIS
molecules from the plasma membrane or to posttransla-
tional modifications affecting NIS activity or stability.
NO donors inhibit forskolin (FSK)- and cAMP-
stimulated I uptake
In thyroid cells, TSH stimulates I uptake through a
cAMP-mediated increase in NIS gene expression. Activa-
tion of the cAMP pathway by FSK, an adenylyl cyclase
activator, or by cAMP analogs mimics TSH-induced I
uptake (3, 33). Therefore, we analyzed the effect of NO
donors onFSK- or dibutyryl-cAMP (dbcAMP)-stimulated
I uptake in FRTL-5 cells. Consistent with previous find-
ings (33), FSK and dbcAMP treatment induced I uptake.
In addition, SNP and GSNO reduced FSK- and dbcAMP-
increased I uptake (Figure 3A), suggesting that the effect
of NO occurs downstream of TSH receptor (TSHR) ac-
tivation and cAMP synthesis. Supporting these observa-
tions, Bazzara et al (13) reported that SNP concentrations
below 500M did not significantly affect TSH-triggered
cAMP production in rat thyrocytes.
We further investigated TSHR protein expression in
response to NO donors. Treatment of FRTL-5 cells with
Figure 1. NO donors inhibit TSH-induced I uptake. A, I uptake in
FRTL-5 cells stimulated with 0.5-mIU/mL TSH in the presence or
absence of 50M–500M SNP for 24 hours. I uptake results are
expressed as pmol I/g DNA. *, P  .05 vs basal condition; †, P 
.05 vs TSH-treated cells. B, I uptake in FRTL-5 cells incubated with
0.5-mIU/mL TSH in the presence or absence of 200M SNP or GSNO,
and 100M SPNO for 24 hours. The NO scavenger cPTIO (200M) was
incubated with the media containing the NO donors for 30 minutes
before addition to the cells. *, P  .05 vs basal condition; †, P  .05 vs
TSH-treated cells; #, P  .05 vs TSH treated in the absence of cPTIO. C,
Representative cell surface biotinylation assay measuring NIS
expression at the plasma membrane in FRTL-5 cells stimulated with
0.5-mIU/mL TSH in the presence or absence of the indicated NO
donors for 24 hours. Immunoblot analysis only revealed an
approximately 80-kDa plasma membrane-located fully glycosylated NIS
polypeptide. Expression of the plasma membrane protein E-cadherin
was used as a loading control. Undetectable -tubulin staining
indicated the absence of cytoplasmic protein contamination (data not
shown). Fold change (FC) represents the mean of results from 3
independent experiments. nd, not detectable. *, P  .05 vs TSH-
treated cells.
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SNP or GSNOdid not significantly modify TSHR protein
expression (Figure 3B), ruling out the possibility that
changes in TSHR expression mediate the effect of NO
donors on TSH-stimulated I uptake. Moreover, we ex-
amined changes in the activity of the cAMP-responsive
vector 5xCRE-Luc under TSH stimulation in the presence
of NO donors for 24 hours. In FRTL-5 cells transiently
transfected with 5xCRE-Luc, neither SNP nor GSNO sig-
nificantly affected the activity of the TSH-induced cAMP-
responsivevector (Figure3C), indicating thatNOdonorsdid
notmodulate theCRE-dependent cAMP-induced transcrip-
tional effect. Specificity in the response of 5xCRE-Luc to
TSHstimulationwasmeasured in thepresenceof theprotein
kinase A (PKA) inhibitor H89 (Figure 3C). Complementa-
rily, we determined the effect of NO donors on the reporter
activity of 5xCRE-Luc upon stimulation with either FSK or
dbcAMP. NO donors did not regulate FSK- or dbcAMP-
stimulated cAMP-responsive vector activity (Supplemental
Figure 3), supporting the notion that the effect of NO
occurs independently of the activation by the PKA-depen-
dent cAMP signaling pathway of the transcription factor
cAMP-response element-binding protein.
NO donors inhibit TSH-stimulated NIS
transcriptional expression
Adecrease in I transport may be the result of different
mechanisms, such as blockage of NIS activity, a decrease in
NISexpressionat theplasmamembrane,oradecrease inNIS
protein biogenesis. Therefore, because NO donors reduced
I uptake in thyroid cells (Figure 1, A
and B) independently of posttransla-
tional modifications (Figure 2), we in-
vestigated whether NO donors mod-
ulate TSH-stimulated NIS protein
expression. We observed that treat-
ment with SNP (50M–500M) for
24 hours significantly reduced TSH-
stimulatedNISprotein expression in a
concentration-dependent manner
(Figure 4A). Consistent with this, we
observed that the NO donors GSNO
andSPNOsignificantly reducedTSH-
stimulated NIS protein expression
(Figure 4B). Interestingly, our data
suggest that NO donors repress NIS-
mediated I uptake by reducing NIS
protein biogenesis, causing fewer NIS
molecules to reach the plasma
membrane.
To investigate the mechanism in-
volved in NO-reduced NIS protein
expression, we measured TSH-stim-
ulated NIS mRNA expression in the
presence of various NO donors. Incubation of FRTL-5
cells with SNP, GSNO, or SPNO for 24 hours led to NIS
mRNA levels significantly lower than those observed in
control cells (Figure 4C), suggesting that NO-reduced
TSH-stimulated NIS expression involves transcriptional
repression of the NIS gene.
Complementarily, to investigateNO-inducedNIS gene
transcriptional repression, we assessed the effect of NO
donors on theNIS gene regulatory sequence. FRTL-5 cells
transfected with the luciferase reporter construct pNIS-
2.8were treatedwith SNP orGSNO (200M) in the pres-
ence of TSH for 24 hours. Consistent with previous find-
ings (21), TSH stimulated pNIS-2.8 reporter activity,
whereas NO donors induced significant repression of
TSH-induced NIS transcriptional activation (Figure 4D).
We further investigated the NIS gene regulatory region
responsible for NO-induced NIS down-regulation by an-
alyzing the transcriptional activity of a 5-deleted NIS re-
porter construct missing the NUE region (pNIS-2.0). In
accordance with previous findings (4), the far-upstream
enhancer NUE was required for full TSH stimulation of
NIS gene transcriptional activation, whereas NO donors
had no effect on the transcriptional activity of the NIS
reporter construct pNIS-2.0 (Figure 4D). These findings
suggest thatNO represses TSH-dependent transcriptional
activation of the NIS gene by a mechanism involving cis-
elements within the NUE region.
Figure 2. NO donors do not modulate NIS expression at the posttranscriptional level. A, I
uptake in TSH-starved FRTL-5 cells stably expressing HA-NIS incubated with 200M SNP or GSNO
for 24 hours. I transport assays were performed in the absence or presence of the NIS competitive
inhibitor perchlorate (ClO4
). Results are expressed as pmol I/g DNA. B, Representative
immunoblot assessing HA expression in FRTL-5 cells permanently expressing HA-NIS. TSH-starved
cells were stimulated with 0.5-mIU/mL TSH for 24 hours. TPO expression was used to
evaluate TSH responsiveness, and -actin was used as a loading control. Fold change (FC)
represents the mean of results from at least 3 independent experiments. C, Representative
histograms showing total NIS expression (total) and NIS expression at the plasma membrane
(surface) quantified by flow cytometry using an anti-HA antibody. HA-NIS-expressing FRTL-5
cells were incubated with 200M NO donor in the presence of 0.5-mIU/mL TSH for 24
hours. Geometric mean  SD of results from 3 independent experiments: TSH, 128  12;
TSH  SNP, 118  8; TSH  GSNO, 122  6 (total); TSH, 137  14; TSH  SNP, 133  18;
and TSH  GSNO, 132  15 (surface). Data from negative controls without the primary
antibody are shown in solid gray histograms.
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NO donors do not modulate Pax8 transcriptional
activity
The transcription factor Pax8 is involved in maintain-
ing thyroid differentiation, and is essential for the expres-
sion of thyroid differentiation markers required for thy-
roid hormone biosynthesis (34). In particular, Pax8
expression is essential for NIS gene expression. The far-
upstream enhancer NUE contains 2 functionally relevant
Pax8-binding sites surrounding a central cAMP-response
element-like element (5). Therefore, we assessed the effect
of NO donors on Pax8 protein expression in response to
TSH treatment.Neither SNP (50M–200M)norGSNO
(200M) modulates TSH-up-regulated Pax8 protein ex-
pression (Figure 5, A and B). In accordance, NO donors
did not significantly affect Pax8mRNA levels (Figure 5C).
Subsequently, we tested the effect of NO donors on Pax8
transcriptional activity in response to TSH stimulation
usinga constructdriving the expressionof luciferaseunder
the control of Pax8 (5xPax8-Luc). None of the tested NO
donors significantly reduced TSH-stimulated Pax8-de-
pendent transcriptional activity (Figure 5D).
Complementarily, we investigated the effect of NOdo-
nors on a TSH-responsive NIS enhancer region (NUE)
construct lacking Pax8-binding sites. FRTL-5 cells were
transfected with the indicated NUE mutant constructs
linked to the thymidine kinase promoter and treated with
200MNO donors in the presence of TSH for 24 hours.
Consistent with the findings indicating that NO donors
repress NIS gene transcription by a mechanism involving
cis-elements within the NUE region (Figure 4D), we ob-
served that NO donors significantly repressed TSH-stim-
ulated pNUE reporter activity (Figure 5E). Interestingly,
mutagenesis at 2 Pax8-binding sites (Pax8-A and Pax8-C)
resulted in dissimilar responses to NO donors. Although
both reporters respond significantly to TSH stimulation,
NO donors repressed pNUE-A activity, whereas disrup-
tion of Pax8-binding site C (pNUE-C) impaired NO re-
sponsiveness (Figure 5E). By contrast, the NIS enhancer
construct lacking both Pax8-binding sites (pNUE-AC) is
mostly insensitive to TSH stimulation (Figure 5E) (4).
Hence, although Pax8-binding site C (NUE-C) modulates
the transcriptional activity of the NUE enhancer in re-
sponse to NO donors, Pax8 transcriptional activity is not
affected by NO donors (Figure 5D), suggesting that bind-
ing of Pax8 to Pax8-binding site C is required for NO to
modulate NIS gene expression. Consistent with this no-
tion,wehavepreviouslydescribeda functional interaction
complex composed of Pax8 and the NF-B-subunit p65
that synergistically regulates NIS transcriptional expres-
sion in response to external stimulus (6).
NO donors repress p65-dependent NIS expression
Given that the NF-B p65 subunit induces NIS gene
expression, and the importance of binding of Pax8 to the
cis-regulatory element Pax8-C to functionally synergize
with p65, which binds to theNUE-C-adjacent B-binding
site (6), we further investigated whether NO suppresses
TSH-dependent NIS gene expression by repressing TSH-
induced NF-B signaling.
Induction of NF-B signaling in FRTL-5 cells after
TSHR activation has been reported previously (35, 36).
Under basal conditions, transcriptionally active NF-B
subunits are sequestered in the cytoplasm as inactive com-
plexes bound to members of the IB family (37). In the
canonical pathway, NF-B-activating agents induce the
Figure 3. NO donors do not inhibit the cAMP signaling pathway
activating the transcription factor cAMP-response element-binding
protein. A, I uptake in FRTL-5 cells stimulated with 0.5-mIU/mL TSH,
10M FSK, or 0.5mM dbcAMP in the presence or absence of 200M
NO donor for 24 hours. Results are expressed as pmol I/g DNA. *,
P  .05 vs basal condition; †, P  .05 vs TSH-, FSK-, or dbcAMP-
treated cells. B, Representative immunoblot analysis of TSHR protein
expression in FRTL-5 cells treated with 200M NO donor in the
presence of 0.5-mIU/mL TSH for 24 hours. -Actin was used as a
loading control. Fold change (FC) represents the mean of results from
at least 3 independent experiments. C, Relative activity of the cAMP-
responsive vector 5xCRE-Luc in response to 200M SNP or GSNO in
the presence of 0.5-mIU/mL TSH for 24 hours. The PKA inhibitor H89
(10M) was added 30 minutes before TSH stimulation. *, P  .05 vs
basal condition; †, P  .05 vs TSH-treated cells.
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phosphorylation and subsequent proteasomal degrada-
tion of IB proteins, causing NF-B subunits to enter the
nucleus and regulate gene transcription (38). Using im-
munoblotting, we studied 2 hallmarks of NF-B signaling
activation, IB- degradation and nuclear accumulation
of p65, in FRTL-5 cells treated with TSH in the presence
of NOdonors for 1 hour.We observed IB- degradation
(Figure 6A) and nuclear accumulation of p65 (Figure 6B)
in response to TSH treatment; coincubation with NO do-
nors significantly affected neither IB- degradation nor
p65 nuclear recruitment, suggesting that NO does not re-
press TSH-activated NF-B signaling. We subsequently
tested the ability of NO donors to regulate TSH-induced
NF-B-dependent gene expression in thyroid cells using an
artificial NF-B reporter (pNF-B-Luc). FRTL-5 cells trans-
fected with the luciferase reporter pNF-B-Luc were incu-
bated withNOdonors in the presence of TSH for 24 hours.
We observed that TSH-induced pNF-B-Luc reporter activ-
ity was significantly reduced in the presence of NO donors,
suggesting that NO represses TSH-induced NF-B-depen-
dent gene transcription (Figure 6C). Assay specificity was
tested in the presence of the NF-B-specific inhibitor BAY
11–7082 (Figure 6C).
NF-B activity is modulated by
negative regulators that are them-
selves highly regulated NF-B tar-
gets. In particular, IB proteins are
among the earliest NF-B-induced
targets that play an important role in
terminating NF-B response (39).
Therefore,wemeasuredIB-mRNA
expression to determine whether NO
donors repress TSH-induced NF-B
transcriptional activity. As expected,
we observed a significant increase in
IB- mRNA expression in response
to treatment with TSH for 24 hours
(Figure 6D). Consistent with the NO-
repressed pNF-B-Luc reporter activ-
ity, TSH-induced IB- mRNA ex-
pression was significantly reduced in
NO donor-treated cells (Figure 6D).
We further investigated the role of
NF-B as a potential target of NO-
induced NIS transcriptional repres-
sion. FRTL-5 cells were transfected
with a pNUE reporter whose B-
binding site was disrupted by site-di-
rected mutagenesis (pNUE-B MT)
and subjected to treatment with NO
donors in the presence of TSH for 24
hours. Interestingly, although dis-
ruption of the B-binding site reduced TSH-induced NIS
promoter activity (6), it rendered NO donors completely
unable to repressTSH-inducedNIS enhancer activity (Fig-
ure 6E).
We further examined thebindingofNF-B subunit p65
to the NIS promoter using ChIP assays. In line with pre-
vious findings (6), quantitativeChIP analysis revealed p65
enrichment in sequences spanning the B site within the
NUE region in response to treatment with TSH for 1 hour
(Figure 6F). Moreover, NO donor treatment significantly
reduced the TSH-induced binding of p65 to the NIS pro-
moter. In the control experiment, p65 enrichment in the
immunoprecipitates was consistently reduced in the pres-
ence of BAY11–7082 (Figure 6F). Therefore, these results
indicate that NO decreased TSH-stimulated NIS tran-
scriptional expression by impairing the binding of the
NF-B subunit p65 to the NIS promoter.
NO donor-induced p65 S-nitrosylation inhibits NIS
transcriptional expression
NO-induced p65 S-nitrosylation is a posttranscrip-
tional mechanism important for regulating the binding of
p65 to DNA and thus inhibiting p65-mediated gene ex-
Figure 4. NO donors inhibit TSH-stimulated NIS transcriptional expression. A and B,
Representative immunoblot analysis of NIS protein expression in FRTL-5 cells stimulated with 0.5-
mIU/mL TSH in the presence of NO donors at the indicated concentrations for 24 hours. The NIS
electrophoretic pattern showed an approximately 80-kDa fully glycosylated and an approximately
55-kDa partially glycosylated polypeptide. -Actin was used as a loading control. Densitometric
analysis was performed to determine the relative expression of fully glycosylated NIS normalized
to -actin. Fold change (FC) represents the mean of results from at least 3 independent
experiments. nd, not detectable. *, P  .05 vs TSH-treated cells. C, Relative NIS mRNA expression
assessed by RT/qPCR. Cells were stimulated with 200M SNP or GSNO, or 100M SPNO, in the
presence of 0.5-mIU/mL TSH for 24 hours. Results are shown as FC relative to the mRNA levels of
untreated cells. *, P  .05 vs basal condition; †, P  .05 vs TSH-treated cells. D, FRTL-5 cells were
transiently transfected with the indicated NIS promoter constructs linked to luciferase. Starved
cells were treated with 200M NO donor in the presence of 0.5-mIU/mL TSH for 24 hours.
Results are expressed as luciferase activity normalized to that of -galactosidase and relative to
basal activity for each construct. *, P  .05 vs basal condition; †, P  .05 vs TSH-treated cells.
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pression (20). Therefore, considering that NO donors in-
hibited the recruitment of p65 to the NUE region, we in-
vestigated the role of S-nitrosylation of p65 at Cys-38 in
NO-repressedNIS expression. FRTL-5 cellswere cotrans-
fected with the reporter pNUE along with an expression
vector encoding p65 in which Cys-38 was replaced with
the nonnitrosylatable residue serine (C38S) or with wild-
type p65 as a control. After starvation, cells were treated
with NO donors in the presence of TSH for 24 hours.
Interestingly, impairment of Cys-38 S-nitrosylation pre-
vented NO-induced NIS transcriptional repression (Fig-
ure 7A). Importantly, using a similar experimental ap-
proach, we demonstrated that C38S p65 does not affect
TSH-induced NF-B-dependent reporter activity (Figure
7B). Immunoblot analysis demonstrated equal p65 pro-
tein expression in wild-type and C38S p65-transfected
cells (Figure 7C). Overall, these data suggest that NO-
mediated posttranscriptional modi-
fication of p65 at Cys-38 constitutes
an essential step in repressing p65-
dependent NIS transcriptional
expression.
To determine whether NO-in-
ducedp65 transcriptional repression
is mediated by S-nitrosylation, we
evaluated the presence of S-nitrosy-
lated p65 in cell lysates generated
from FRTL-5 cells treated with dif-
ferent NO donors in the presence of
TSH for 1 hour. Using biotin switch
assays (40), p65 S-nitrosylation was
detectable in response to the nitrosy-
lation agent GSNO, unlike control
and TSH-treated cells (Figure 7D).
We further established that p65 S-
nitrosylation was not affected only
by the nitrosylating agent GSNO,
because SNP- and SPNO-treated
cells also showed detectable p65 S-
nitrosylation (Figure 7D). Taken to-
gether, our data demonstrate that
NO-induced p65 S-nitrosylation
modulates TSH-dependent NIS
transcriptional expression (Figure
7E).
Discussion
Thyroid function is strictly regulated
byTSH, althoughother factors, such
as intrathyroidal I levels and thy-
roid follicle-stored thyroglobulin,
function as autocrine negative feedback regulators of thy-
roid hormone biosynthesis. Endogenous TSH-induced
NO production has been implicated in the regulation of
the thyroid function, because NO signaling controls sev-
eral events in thyroid hormonogenesis (16). Previous ob-
servations have indicated that NO donors inhibit I up-
take in different thyroid cell models. Kasai et al (41) and
Costamagna et al (14) described a regulatory role for NO
as an inhibitor of I organification in primary cultures of
human and bovine thyroid follicles. Consistent with this,
NOS II-produced NO partially mediates proinflamma-
tory-cytokine-repressed thyroid peroxidase (TPO) and
thyroid oxidase expression in human thyrocytes (42, 43).
More recently, Bazzara et al (13) have reported that NO
donors inhibit TSH-induced TPO and thyroglobulin
mRNA expression in rat thyroid cells.
Figure 5. NO donors do not modulate Pax8 transcriptional activity. A and B, Representative
immunoblot analysis of Pax8 protein expression in FRTL-5 cells stimulated with 50M–500M
SNP or 200M GSNO in the presence of 0.5-mIU/mL TSH for 24 hours. -Actin expression was
used as a loading control. Fold change (FC) represents the mean of results from at least 3
independent experiments. *, P  .05 vs nontreated cells. C, Relative Pax8 mRNA expression
levels in cells stimulated with 200M SNP or GSNO, or 100M SPNO, in the presence of 0.5-
mIU/mL TSH for 24 hours. Results are given as FC relative to the mRNA levels of untreated cells.
*, P  .05 vs basal condition. D, Relative activity levels of the Pax8 reporter 5xPax8-Luc in
response to 200M SNP or GSNO, or 100M SPNO, in the presence of 0.5-mIU/mL TSH for 24
hours. *, P  .05 vs basal condition. E, Upper panel, Schematic representation of the 2495 to
2264 (bp) DNA fragment of the far-upstream enhancer NUE cloned 5-upstream of the
thymidine kinase promoter (TKp). Shapes represent the indicated transcription factor-binding
sites. Lower panel, Cells were transiently transfected with the indicated Pax8-binding site missing
pNUE constructs linked to luciferase and treated with 200M NO donor in the presence of 0.5-
mIU/mL TSH for 24 hours. Results are expressed as luciferase activity normalized to that of -
galactosidase and relative to basal activity for each construct. *, P  .05 vs basal condition;
†, P  .05 vs TSH-treated cells.
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Thyroid microvasculature is key for sustaining thyroid
function, and thyrocytes play a critical role in its regula-
tion. In particular, NOmay participate in controlling thy-
roid vascularity and blood flow during thyroid dysfunc-
tion. Colin et al (10) reported abundant NOS III
expression in thyroid cells during
goitrogenesis, because animals
treatedwith theNOS inhibitorN-ni-
tro-L-argininemethyl ester showeda
36%reduction in vasculature during
goiter formation. Subsequently, Co-
lin et al (9) observed an increase in
NOS III protein in samples from hy-
perthyroid patients, whereas NOS
III was barely detectable in hypothy-
roid patients. In accordance with
these findings,Gérard et al (12) dem-
onstrated that NOS III expression is
restricted to active thyroid follicles,
thus suggesting that paracrine NO-
promoted microvascular blood flow
is required to sustain hormone pro-
duction. Recently, Craps et al (44)
demonstrated that I deficiency-in-
duced thyroidal blood flow relies on
increased NOS III-mediated NO
production. These observations are
consistent with the existence of a
close relation between thyroid fol-
licular and endothelial cells, inwhich
TSH-independent mechanisms may
stimulate thyroid cell metabolism to
promote angiogenesis.
Physiological mediators of NO
activity involve canonical cGMP/
cGK signaling and the noncanonical
pathway in which NO regulates pro-
tein function through S-nitrosylation
(17). In dog thyroid slices, Ca2 sig-
naling activation significantly in-
creased NOS-mediated cGMP pro-
duction (11). Similarly, NO donors
induced dose-dependent cGMP pro-
duction in thyroid cells (13). Bocanera
et al (15) reported acute repression of
I uptake in response to cGK activa-
tors incalf thyroidprimarycultures. In
agreementwith this, Bazzara et al (13)
demonstrated that long-term incuba-
tion with NO donors reduced I up-
take involving cGK signaling activa-
tion in rat thyrocytes. Conversely,
although blockage of NOS activity reversed cytokine-abro-
gated cell proliferation,NOdonors, but not cGMP analogs,
inhibited cell growth, suggesting thatNOalso exerts cGMP-
independent inhibitory effects on human thyrocytes (45).
Gérard et al (42) postulated thatNOmay control I organi-
Figure 6. NO donors inhibit TSH-induced NF-B transcriptional activity. A, Representative
immunoblot analysis showing IB- and p65 protein levels in response to 200M NO donor in
the presence of 0.5-mIU/mL TSH for 1 hour. -Actin expression was used as a loading control.
Fold change (FC) represents the mean of results from at least 3 independent experiments. *, P 
.05 vs basal condition. B, Representative immunoblot analysis of p65 nuclear recruitment in
response to 200M NO donor in the presence of 0.5-mIU/mL TSH for 1 hour. Staining of the
cytoplasmic marker -tubulin or the nuclear marker histone H1 served to establish the separation
of nuclear from cytoplasmic fractions. -Actin expression was used as a loading control. FC
represents the mean of results from at least 3 independent experiments. *, P  .05 vs basal
condition. C, Relative activity of the NF-B reporter vector pNF-B-Luc in response to 200M SNP
or GSNO, or 100M SPNO, in the presence of 0.5-mIU/mL TSH for 24 hours. The NF-B inhibitor
BAY 11–7082 (1M) was added 30 minutes before TSH stimulation. *, P  .05 vs basal
condition; †, P  .05 vs TSH-treated cells. D, Relative IB- mRNA expression in cells stimulated
with 200M SNP or GSNO, or 100M SPNO, in the presence of 0.5-mIU/mL TSH for 24 hours.
Results are given as FC relative to the mRNA levels of untreated cells. *, P  .05 vs basal
condition; †, P  .05 vs TSH-treated cells. E, Cells were transiently transfected with the indicated
pNUE constructs linked to luciferase and treated with 200M NO donor in the presence of 0.5-
mIU/mL TSH for 24 hours. Results are expressed as luciferase activity normalized to that of
-galactosidase and relative to basal activity for each construct. *, P  .05 vs basal
condition; †, P  .05 vs TSH-treated cells. F, Starved cells were treated with 200M NO
donor in the presence of 0.5-mIU/mL TSH for 1 hour before cross-linking and a further ChIP
assay. BAY 11–7082 (1M) was added 30 minutes before TSH stimulation. Results are
expressed as relative FC (p65 IP/p65 input). nd, not detectable. *, P  .05 vs basal condition;
†, P  .05 vs TSH-treated cells.
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fication through an S-nitrosylation-dependent process in-
volving proteasome-mediated TPO and thyroid oxidase
degradation. Here, we propose a novel cGMP-indepen-
dent mechanism for NO-induced inhibition of NIS-medi-
ated Iuptake in rat thyroid cells involving transcriptional
repression of NF-B-activated NIS gene expression in re-
sponse to stimulation by TSH. Our data indicate that NO
donors repress TSH-induced NIS gene expression by re-
ducing the transcriptional activity of the NF-B subunit
p65. S-nitrosylation of p65 at Cys-38 impairs its binding
to DNA and thus suppresses p65-dependent gene expres-
sion (20). Consistent with this, overexpression of the
nonnitrosylatable C38S p65 mu-
tant abrogated NO-repressed NIS
promoter activity. Moreover, we
detected p65 S-nitrosylation in re-
sponse toNOdonor treatment using
the biotin-switch technique. Taken
together, these findings indicate that
p65 S-nitrosylation plays a previ-
ously undiscovered role in regulating
TSH-stimulated NIS transcriptional
expression.
Mounting evidence supports a
role for S-nitrosylation as a major
NO-dependent posttranslational
mechanism in the direct regulation
of protein function (17). In recent
years, several studies have reported
that S-nitrosylation participates in
regulating physiological hormone-
stimulated cellular processes. In hu-
man umbilical vein endothelial cells,
17-estradiol stimulates protein
S-nitrosylation by increasing NOS
III-generated NO levels (46). S-ni-
trosoproteome analysis has sug-
gested that S-nitrosylation regulates
several endothelial functions, in-
cludingmitochondrial functions and
cellular cytoskeleton remodeling
(46–48). In addition, NO-induced
S-nitrosylation of the -isoform of
the estrogen receptor at Zn2-coor-
dinating cysteine residues in the 2
major DNA-binding Zn-finger do-
mains inhibits the binding of the re-
ceptor to DNA, repressing the
genomic actions of estrogen (49). In
pancreatic -cells, insulin regulates
the activity of glucokinase by mod-
ulating its association with insulin-
secreting granules. Insulin-stimulated NO production
leads to the S-nitrosylation of glucokinase and its disso-
ciation from secretory granules, thus reducing the cellular
activity of glucokinase, because secretory granules func-
tion as a storage pool for glucokinase (50). Moreover, in
obesity, insulin resistance has been associated with in-
creased S-nitrosylation of proteins involved in the insulin
signaling cascade (51). Increased S-nitrosylation has been
observed in obesity-associated adipose tissue and sug-
gested to contribute to adipocyte resistance to insulin. In
adipocytes, S-nitrosylation targets the antilipolytic action
of insulin, leading to the dysregulated lipolysis observed in
Figure 7. p65 S-nitrosylation mediates NO donor-induced NIS transcriptional repression. A,
FRTL-5 cells were cotransfected with the reporter pNUE along with the expression vector
encoding wild-type or C38S p65. After starvation, cells were treated with 200M SNP or GSNO,
or 100M SPNO, in the presence of 0.5-mIU/mL TSH for 24 hours. Results are expressed as
luciferase activity normalized to that of -galactosidase and relative to pNUE basal activity. *, P 
.05 vs basal condition; †, P  .05 vs TSH-treated cells. B, Relative activity levels of the NF-B-
dependent reporter pNF-B-Luc in response to TSH (0.5 mIU/mL) treatment for 24 hours in FRTL-
5 cells overexpressing wild-type or C38S p65. Results are expressed as luciferase activity
normalized to that of -galactosidase and relative to pNF-B-Luc basal activity. BAY 11–7082
(1M) was used as a specificity control. *, P  .05 vs basal condition; †, P  .05 vs TSH-treated
cells. C, Representative immunoblot analysis of whole-protein extracts obtained from FRTL-5 cells
transiently transfected with wild-type or C38S p65. Exogenously overexpressed wild-type and
C38S p65 were detected with anti-FLAG and anti-p65 antibodies. Loading was assessed by -
actin expression. D, Biotin-switch assay showing p65 S-nitrosylation in response to 200M SNP
or GSNO, and 100M SPNO, in the presence of 0.5-mIU/mL TSH for 1 hour. Undetectable p65
S-nitrosylation was observed in untreated and TSH-treated cells. p65 immunoblots are shown for
both the S-nitrosylated protein (SNO-p65) and the input lysate (p65). E, Summary schematic
representation. Gray arrows indicate partially characterized signaling pathways. AC, adenylate
cyclase.
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the pathogenesis of obesity-associatedmetabolic dysfunc-
tion (52).
Colin et al (9) reported increased expression ofNOS III
in thyroid follicular cells from patients with Graves’ dis-
ease and autonomous toxic adenomas harboring activat-
ing TSHR mutations. Previous results from our group
have revealed the ability of TSH-stimulated endogenously
produced NO to inhibit thyroid cell function and differ-
entiation. Using nonselective NOS inhibitors, we have
shownthat inhibitionofNOSactivity increasesTSH-stim-
ulated thyroid differentiation markers and cell prolifera-
tion, revealing that there may be an inhibitory autocrine
pathway that modulates TSH-stimulated thyroid cell
function (16). Accumulated evidence led us to hypothesize
that TSH-stimulated NF-B-mediated gene expression
might be counterbalanced by TSH-dependent stimulation
of NOS III-produced NO, leading to inhibition of NF-B
transcriptional activity through S-nitrosylation. Accord-
ingly, Kelleher et al (20) suggested a counter-regulatory
mechanism by which NF-B-induced NOS II activity in
response to proinflammatory cytokines down-regulated
NF-B-dependent gene expression through S-nitrosyla-
tion in macrophages, thus providing a feedback loop lim-
iting inflammation.
Pathological conditions are often associated with NOS
overexpression and unregulated NO production, result-
ing in inappropriate S-nitrosylation-regulated cellular
processes that may contribute to pathological phenotypes
(53, 54). Although NO and other oxygen radicals have
been shown to be important factors related to tumorigen-
esis (55, 56), the role of NO in thyroid carcinogenesis
remains unclear. NOS overexpression has been demon-
strated in papillary thyroid carcinoma and autoimmune
thyroid disease (57). Consistent with this, Nakamura et al
(58) reported increased nitrotyrosine-modified protein
levels, an indicator of NO overproduction, in samples
from primary papillary thyroid tumors. In addition, van
den Hove et al (43) have proposed that NO mediates cy-
tokine-induced cytotoxic effects and functional injuries to
follicular cells in autoimmune thyroiditis. In thyroid can-
cer, NOS II-generated NO-mediated S-nitrosylation and
the subsequent nuclear translocation of glyceraldehyde-
3-phosphate dehydrogenase might be implicated in tu-
mor necrosis factor-related apoptosis-inducing ligand-
mediated anaplastic thyroid cancer cell death (59). In
addition, NO-mediated long-term inhibition of thyroid
hormonogenesis could shed light on human thyroid pa-
thologies associated with chronic NO production.
The elucidation of the underlying mechanism control-
ling NIS expression in the thyroid may have important
implications not only for understanding the pathways reg-
ulating thyroid hormone biosynthesis but also for the de-
velopment of novel strategies for improvingNIS-mediated
radioiodide therapy for treating thyroid cancer (60).Here,
we have demonstrated that exogenous NO-induced p65
S-nitrosylation represses TSH-stimulated NIS transcrip-
tional expression, thus reducing NIS-mediated I uptake
in rat thyrocytes. Future studies of S-nitrosylation in ra-
dioiodide-refractory thyroid tumors may provide novel
therapeutic strategies for increasing NIS expression,
thereby making possible more effective radiotherapy
regimens.
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